Objectives

Assess the efficiency and safety of Percutaneous pulmonary valve implantation in the Algerian population.

Background

Percutaneous pulmonary valve implantation (PPVI) is a less invasive alternative to surgery in treatment of right ventricular outflow tract dysfunction. This study reports the Algerian experience in PPVI.

Methods

   Between November 2017 and December 2021, 30 patients underwent percutaneous pulmonary valve implantation in our center, CMCI Bouismail, Algiers. The mean age was 18 years (range 11 to 25 years). Follow-up ranged from 3 to 46 months.

The procedures were performed under general anesthesia, echocardiography and fluoroscopic guidance

Prospective follow-up using transthoracic echocardiography  was done until December 2022.

Results

Significant reduction in right ventricular systolic pressure was noticed (from 77±21 to 48±17 mm Hg, P<0.001).  One patient (3.7 %) was reoperated one year later for important residual right ventricular outflow tract stenosis. Tow patients (7.4 %) developed infective endocarditis six months and one years later. Freedom from transcatheter reintervention was 96%, one patient underwent postprocedural valve dilatation for a residual RV stenosis.